$XRTX News

Last published 4h ago

4h agoXRTXXORTX Patent Allowed for XRx-101 Program by Japan Patent OfficeGlobeNewswireJapan Patent Office allows claims directed to xanthine oxidase inhibitor compositions for acute kidney injury and other health consequences of viral infection; once registered, patent expected to remain in force until March 2041
1mo agoXRTXXORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for GoutGlobeNewswire● Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- XORTX
1mo agoXRTXXORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market OpportunityGlobeNewswireCALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX), a late-stage clinical pharmaceutical company focused on developing innovative
2mo agoXRTXXORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™GlobeNewswire● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) -- XORTX
2mo agoXRTXXORTX Re-Engages Investor Relations ProgramGlobeNewswireCALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") announces that, following completion of its previously announced voluntary delisting from the TSX
2mo agoXRTXXORTX Announces Termination and Postponement of Investor Relations ProgramGlobeNewswireCALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused
3mo agoXRTXXORTX Announces Director ResignationGlobeNewswireCALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
3mo agoXRTXXORTX Appoints New DirectorGlobeNewswireCALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
5mo agoXRTXXORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEOGlobeNewswireCALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
5mo agoXRTXXORTX Announces Election to Voluntary Delist from the TSX Venture ExchangeGlobeNewswireCALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
5mo agoXRTXXORTX Announces Closing of US$5 Million Public OfferingGlobeNewswireCALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
5mo agoXRTXE.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public OfferingGlobeNewswireNEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the exclusive
6mo agoXRTXXORTX Announces US$5 Million Public OfferingGlobeNewswireCALGARY, Alberta, May 14, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing
6mo agoXRTXXORTX Meets Nasdaq Continued Listing RequirementsGlobeNewswireCALGARY, Alberta, April 21, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
7mo agoXRTXXORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic AssetGlobeNewswire• VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc.
7mo agoXRTXXORTX Confirms Effective Date of Share ConsolidationGlobeNewswireCALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
7mo agoXRTXXORTX Announces Results of Annual and Special Meeting of ShareholdersGlobeNewswireCALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
7mo agoXRTXXORTX Announces Change of Effective Date of Share ConsolidationGlobeNewswireCALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing
7mo agoXRTXXORTX Announces Share ConsolidationGlobeNewswireCALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
7mo agoXRTXXORTX Reports that Shareholders Approved the Share Consolidation at the Annual General MeetingGlobeNewswireCALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing
8mo agoXRTXXORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share ConsolidationGlobeNewswireYour vote is important – Vote well in advance of the proxy voting deadline: March 20, 2026XORTX's board of directors unanimously recommends that Shareholders vote FOR all resolutionsShareholder questions or need voting
8mo agoXRTXXORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of ShareholdersGlobeNewswireCALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
9mo agoXRTXXORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus BiosystemsGlobeNewswireCALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing
10mo agoXRTXXORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate UpdateGlobeNewswireCALGARY, Alberta, Dec. 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Announces Closing of US$1.1 Million Registered Direct OfferingGlobeNewswireCALGARY, Alberta, Oct. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Announces Pricing of US$1.1 Million Registered Direct OfferingGlobeNewswireCALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price DeficiencyGlobeNewswireCALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewswireCALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus BiosystemsGlobeNewswireCALGARY, Alberta, Oct. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing
1y agoXRTXJoin XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10GlobeNewswireCALGARY, Alberta, Sept. 04, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing
1y agoXRTXXORTX Initiates IND Preparation for XORLO™ in Gout ProgramGlobeNewswireCALGARY, Alberta, Sept. 03, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing
1y agoXRTXXORTX Completes USD $114,500 Private PlacementGlobeNewswireNOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company")
1y agoXRTXXORTX Provides Corporate Update and Planned Activities for 2025 / 2026GlobeNewswireCALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing
1y agoXRTXXORTX Announces USD $114,500 Private PlacementGlobeNewswireCALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing
1y agoXRTXXORTX Completes Non-Brokered Private Placement of UnitsGlobeNewswireNot For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company")
1y agoXRTXXORTX Announces USD $925,000 Private PlacementGlobeNewswireNOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company")
1y agoXRTXXORTX Announces USD $3 Million OfferingGlobeNewswireCALGARY, Alberta, May 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Provides Update on FDA Type B Meeting RequestGlobeNewswire● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX,
1y agoXRTXXORTX Announces Grant of European PatentGlobeNewswireCALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewswireCALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Announces Update for Discussion with the FDAGlobeNewswire● Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt:
1y agoXRTXXORTX Commences Gout Program NDA Discussions with the FDAGlobeNewswire● Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, Feb. 24, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX,
1y agoXRTXXORTX to Present at Microcap ConferenceGlobeNewswireCALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA)), a late stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Announces Change of AuditorGlobeNewswireCALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Adds Late Stage Gout Program to PipelineGlobeNewswireCALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Strengthens Executive TeamGlobeNewswireCALGARY, Alberta, Dec. 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
1y agoXRTXXORTX Announces Presentation at the Rare and Genetic Disease SummitGlobeNewswireCALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
2y agoXRTXXORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2024GlobeNewswire● Health consequences of chronically high uric acid and xanthine oxidase in polycystic kidney disease in rats, mice and humans ● CALGARY, Alberta, Oct. 24, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc.
2y agoXRTXXORTX Announces Closing of US$1.5 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewswireCALGARY, Alberta, Oct. 18, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on
2y agoXRTXXORTX Announces Pricing of US$1.5 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewswireCALGARY, Alberta, Oct. 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on